AdJane Mucosal Booster White Paper
Analysis based on 9 articles · First reported Sep 10, 2026 · Last updated Sep 10, 2026
The announcement is a single-company strategic and scientific disclosure with no immediate revenue, regulatory, or competitive impact on the broader vaccine market, so it is unlikely to move major indexes or sector valuations. It may draw modest investor attention to AdJane's platform and to the mucosal-immunity niche, with Pfizer and Moderna mentioned only as prior priming vaccines in AdJane's Phase I subset rather than as parties to the strategy.
AdGene Biosciences, a clinical-stage next-generation vaccine platform company based in Delft, Netherlands, announced on September 10, 2026 the publication of a new White Paper titled Boosting mRNA: Mucosal Immunity and a Platform Beyond It. The White Paper sets out a potential new application of AdJane's Neisseria meningitidis native Outer Membrane Vesicle (Nm-nOMV) platform: adding mucosal boosting to established intramuscular respiratory vaccine franchises. The strategy proposes building on the systemic immunity established by intramuscular priming with an intranasal Nm-nOMV booster designed to induce complementary immunity at the respiratory mucosa, a heterologous prime-boost approach that could let vaccine developers retain the benefits and infrastructure of established respiratory vaccines while adding a proprietary mucosal component. AdJane cites its recently completed Phase I study as initial clinical support: in a post-hoc identified subset of participants who had previously received Pfizer and/or Moderna COVID-19 mRNA vaccines, subsequent intranasal administration of an Nm-nOMV vaccine displaying SARS-CoV-2 Spike was well tolerated and induced significant nasal IgA responses. The company says further clinical studies will be required to establish the magnitude, durability and potential clinical relevance of the additional mucosal immune response. AdJane has developed a broad intellectual property portfolio around its Nm-nOMV platform, including protection relating to the platform, manufacturing, mucosal dosing and specific vaccine applications, and has filed separate patent applications covering combinations of OMV technology with mRNA vaccines and respiratory vaccines. Potential applications could extend across COVID-19, influenza, RSV, combination respiratory vaccines and future pandemic preparedness, subject to further development and clinical validation. CEO Anita Gashi framed the approach as starting from vaccines that already protect millions of people.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard